Your browser doesn't support javascript.
loading
Comprehensive characterization of bacterial glycoconjugate vaccines by liquid chromatography - mass spectrometry.
Di Marco, Fiammetta; Hipgrave Ederveen, Agnes L; van Schaick, Guusje; Moran, Alan B; Domínguez-Vega, Elena; Nicolardi, Simone; Blöchl, Constantin; Koeleman, Carolien A; Danuser, Renzo; Al Kaabi, Ali; Dotz, Viktoria; Grijpstra, Jan; Beurret, Michel; Anish, Chakkumkal; Wuhrer, Manfred.
Afiliación
  • Di Marco F; Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, the Netherlands.
  • Hipgrave Ederveen AL; Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, the Netherlands.
  • van Schaick G; Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, the Netherlands.
  • Moran AB; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines and Prevention B.V., Archimedesweg 4-6, 2333 CN Leiden, the Netherlands.
  • Domínguez-Vega E; Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, the Netherlands.
  • Nicolardi S; Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, the Netherlands.
  • Blöchl C; Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, the Netherlands.
  • Koeleman CA; Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, the Netherlands.
  • Danuser R; Janssen Vaccines AG (Branch of Cilag GmbH International), Rehhagstrasse 79, CH-3018 Bern, Switzerland.
  • Al Kaabi A; Janssen Vaccines AG (Branch of Cilag GmbH International), Rehhagstrasse 79, CH-3018 Bern, Switzerland.
  • Dotz V; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines and Prevention B.V., Archimedesweg 4-6, 2333 CN Leiden, the Netherlands; BioTherapeutics Analytical Development, Janssen Biologics B.V., Einsteinweg 101, 2333 CB Leiden, the Netherlands.
  • Grijpstra J; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines and Prevention B.V., Archimedesweg 4-6, 2333 CN Leiden, the Netherlands.
  • Beurret M; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines and Prevention B.V., Archimedesweg 4-6, 2333 CN Leiden, the Netherlands.
  • Anish C; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines and Prevention B.V., Archimedesweg 4-6, 2333 CN Leiden, the Netherlands.
  • Wuhrer M; Center for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, the Netherlands. Electronic address: m.wuhrer@lumc.nl.
Carbohydr Polym ; 341: 122327, 2024 Oct 01.
Article en En | MEDLINE | ID: mdl-38876725
ABSTRACT
Bacterial pathogens can cause a broad range of infections with detrimental effects on health. Vaccine development is essential as multi-drug resistance in bacterial infections is a rising concern. Recombinantly produced proteins carrying O-antigen glycosylation are promising glycoconjugate vaccine candidates to prevent bacterial infections. However, methods for their comprehensive structural characterization are lacking. Here, we present a bottom-up approach for their site-specific characterization, detecting N-glycopeptides by nano reversed-phase liquid chromatography-mass spectrometry (RP-LC-MS). Glycopeptide analyses revealed information on partial site-occupancy and site-specific glycosylation heterogeneity and helped corroborate the polysaccharide structures and their modifications. Bottom-up analysis was complemented by intact glycoprotein analysis using nano RP-LC-MS allowing the fast visualization of the polysaccharide distribution in the intact glycoconjugate. At the glycopeptide level, the model glycoconjugates analyzed showed different repeat unit (RU) distributions that spanned from 1 to 21 RUs attached to each of the different glycosylation sites. Interestingly, the intact glycoprotein analysis displayed a RU distribution ranging from 1 to 28 RUs, showing the predominant species when the different glycopeptide distributions are combined in the intact glycoconjugate. The complete workflow based on LC-MS measurements allows detailed and comprehensive analysis of the glycosylation state of glycoconjugate vaccines.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glicoconjugados / Vacunas Bacterianas / Glicopéptidos Idioma: En Revista: Carbohydr Polym Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glicoconjugados / Vacunas Bacterianas / Glicopéptidos Idioma: En Revista: Carbohydr Polym Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos
...